Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Institut Cancerologie de l'Ouest
InSightec
Centre Oscar Lambret
H. Lee Moffitt Cancer Center and Research Institute
Institut Curie
UNC Lineberger Comprehensive Cancer Center
Virginia Commonwealth University
Maastricht Radiation Oncology
Institut du Cancer de Montpellier - Val d'Aurelle
Hellenic Cooperative Oncology Group
Washington University School of Medicine
MedSIR
Thomas Jefferson University
Inova Health Care Services
Cedars-Sinai Medical Center
National Cancer Institute (NCI)
Taproot Health
University Hospital, Antwerp
University of Chicago
Prelude Therapeutics
Columbia University
University of Southern California
Cedars-Sinai Medical Center
Stanford University
Stanford University
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Seagen Inc.
Mayo Clinic
Eastern Cooperative Oncology Group
Quadriga Biosciences, Inc.
Gan and Lee Pharmaceuticals, USA
Alliance for Clinical Trials in Oncology
Technische Universität Dresden
Centre Hospitalier Universitaire de Besancon
Memorial Sloan Kettering Cancer Center
US Oncology Research
Weill Medical College of Cornell University
Gilead Sciences
Dana-Farber Cancer Institute
National Institutes of Health Clinical Center (CC)
Novartis
Eli Lilly and Company
DEKK-TEC, Inc.
National Institutes of Health Clinical Center (CC)
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
National Institutes of Health Clinical Center (CC)
Celgene